Safety and efficacy of pharmacological treatments for axial spondyloarthritis

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

(2022) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Treat-to-target in axial spondyloarthritis — what about physical function and activity?

(2021) Jürgen Braun et al.   Nature Reviews Rheumatology

Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients

(2021) Kevin Sheng-Kai Ma et al.   Ocular Surface

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis

(2020) Stefano Gentileschi et al.   MEDIATORS OF INFLAMMATION

Nonsteroidal anti-inflammatory drugs and cardiovascular risk – a matter of indication

(2019) Juergen Braun et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Nonsteroidal Anti‐inflammatory Drug use is Associated with Incident Hypertension in Ankylosing Spondylitis

(2019) Jean W. Liew et al.   ARTHRITIS CARE & RESEARCH

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

(2019) Atul Deodhar et al.   LANCET

Safety of treatment options for spondyloarthritis: a narrative review

(2018) Salvatore D’Angelo et al.   Expert Opinion On Drug Safety

The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study

(2018) Marion Couderc et al.   JOURNAL OF RHEUMATOLOGY

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort

(2018) Monika Hebeisen et al.   JOURNAL OF RHEUMATOLOGY

Discontinuing tumour necrosis factor inhibitors in non-radiographic axial spondyloarthritis

(2018) Jürgen Braun   LANCET

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

(2018) Dominique Baeten et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

(2018) Mitsumasa Kishimoto et al.   Modern Rheumatology

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis

(2017) Gareth T. Jones et al.   ARTHRITIS CARE & RESEARCH

Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials

(2017) Zhigao Xu et al.   Experimental and Therapeutic Medicine

Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data

(2017) Michèle Bally et al.   BMJ-British Medical Journal

Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data

(2017) Michèle Bally et al.   BMJ-British Medical Journal

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

(2016) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

(2016) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis

(2016) Xenofon Baraliakos et al.   RHEUMATOLOGY

Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality

(2015) Nisha Nigil Haroon et al.   ANNALS OF INTERNAL MEDICINE

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort

(2014) D. Wallis et al.   RHEUMATOLOGY

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

(2013) R Landewé et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

(2012) Bente Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Differences in physical activity patterns in patients with spondylarthritis

(2012) Emma Haglund et al.   ARTHRITIS CARE & RESEARCH

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

(2011) X. Baraliakos et al.   RHEUMATOLOGY

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

(2008) Robert D. Inman et al.   ARTHRITIS AND RHEUMATISM